Former CEO of Inserm-Transfert, subsidiary of INSERM (French National Institute for Health and Medical Research) Founder and former president of Inserm Transfert Initiative (seed fund dedicated to healthcare young innovative companies) Founder of the Strategic Council for Innovation (secretary general from 2003 to 2005), The Council’s goal is to boost French efforts in the field of research and high technologies and included key figures from France’s science, industry and financial community Biochemist by training (University of South Paris – Orsay).
Several management positions at Bayer HealthCare, then member of the Worldwide Executive Committee as head of WW Business Development, Licensing, Mergers & Acquisitions Previously head of the cardiovascular business at Sandoz More than 25 years of experience in Healthcare mainly in the Pharmaceutical Industry.
15 years of experience in Drug Discovery and Drug Development. He participated in the development of several drug candidates (new chemical entities, peptides and recombinant proteins) that reached clinical stages in different therapeutic areas. Ph.D. in Organic Chemistry from the University Paris-Sud, master of science from Ecole Supérieure de Physique et de Chimie Industrielle of Paris (ESPCI) and Executive MBA from the ESSEC & Mannheim Business School.
More than 20 years experience in the pharmaceutical industry, several positions in R&D and medical affairs in big pharmaceutical companies ( Aventis, Bristol-Myers-Squibb) in the field of cardiology and thrombosis as well as in a start-up company (medical device). MD, cardiologist and graduated in Biostatistics.
Previously, he held operational management and senior leadership positions in major pharmaceutical companies, particularly at Bayer and Pfizer, for eighteen years. Stéphane has been involved in a dozen successful market launches of new treatments.
PharmD from the University of Aix-Marseille and holder of an MBA in Marketing Management from ESSEC.